Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Market Cap currently 53 million

<< Previous

Bullboard Posts

Next >>

Comment by 294everon Oct 15, 2021 1:09pm

244 Views

Post# 34010540

RE:RE:Market Cap currently 53 million

I respectfully disagree
If you want to sell me your shares at a heavy discount which by your tone today I presume would be loss then go ahead, fuel the sell off further.

The balance sheet is solid, They generate some revenue.
These are called trials for a reason. Not every dose is perfect the first time. If you don't have the fortitude to stick it out then rather than bashing quietly sell your shares and move on.

Good Luck to you Sir

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China